In:
Public Health Nutrition, Cambridge University Press (CUP), Vol. 12, No. 12 ( 2009-12), p. 2410-2415
Abstract:
Few studies have been conducted to investigate the influence of recombinant human erythropoietin (rhEPO) on the long-term prognosis of end-stage renal disease (ESRD). Design A retrospective cohort study. Setting The largest regional hospital renowned for haemodialysis in northern Taiwan. Subjects A total of 702 ESRD patients undergoing haemodialysis between 1993 and 2002 were evaluated. Results The rate of overall use of rhEPO, vitamin D 3 or Fe therapy was 62 %. The 10-year survival rate in patients with rhEPO supplementation was statistically more favourable than that in patients without rhEPO (hazard ratio (HR) = 0·38, 95 % CI 0·30, 0·47, P 〈 0·0001). Similar findings were noted for patients receiving vitamin D 3 (HR = 0·36, 95 % CI 0·21, 0·64, P = 0.0004) and Fe (HR = 0·45, 95 % CI 0·33, 0·61, P 〈 0·0001). After adjusting for age, education and aetiology, the administration of rhEPO resulted in statistically significant improvements in long-term survival rate either with (HR = 0·30, 95 % CI 0·22, 0·42) or without (HR = 0·48, 95 % CI 0·38, 0·61) combined use of Fe or vitamin D 3 . Conclusions We demonstrated a reduction in long-term mortality related to supplementation therapy with rhEPO, vitamin D 3 and Fe. The findings provide a justification for the administration of combined supplement therapy in patients undergoing haemodialysis.
Type of Medium:
Online Resource
ISSN:
1368-9800
,
1475-2727
DOI:
10.1017/S1368980009005308
Language:
English
Publisher:
Cambridge University Press (CUP)
Publication Date:
2009
detail.hit.zdb_id:
2016337-X
SSG:
21
Bookmarklink